Calpain released from dying hepatocytes mediates progression of acute liver injury induced by model hepatotoxicants.
Liver injury is known to progress even after the hepatotoxicant is long gone and the mechanisms of progressive injury are not understood. We tested the hypothesis that hydrolytic enzymes such as calpain, released from dying hepatocytes, destroy the surrounding cells causing progression of injury. Calpain inhibitor, N-CBZ-VAL-PHE-methyl ester (CBZ), administered 1 h after a toxic but nonlethal dose of CCl(4) (2 ml/kg, ip) to male Sprague Dawley rats substantially mitigated the progression of liver injury (6 to 48 h) and also led to 75% protection against CCl(4)-induced lethality following a lethal dose (LD75) of CCl(4) (3 ml/kg). Calpain leakage in plasma and in the perinecrotic areas increased until 48 h and decreased from 72 h onward paralleling progression and regression of liver injury, respectively, after CCl(4) treatment. Mitigation of progressive injury was accompanied by substantially low calpain in perinecrotic areas and in plasma after CBZ treatment. Normal hepatocytes incubated with the plasma collected from CCl(4)-treated rats (collected at 12 h when most of the CCl(4) is eliminated) resulted in extensive cell death prevented by CBZ. Cell-impermeable calpain inhibitor E64 also protected against progression of CCl(4)-induced liver injury, thereby confirming the role of released calpain in progression of liver injury. Following CCl(4) treatment, calpain-specific breakdown of alpha-fodrin increased, while it was negligible in rats receiving CBZ after CCl(4). Hepatocyte cell death in incubations containing calpain was completely prevented by CBZ. Eighty percent of Swiss Webster mice receiving a lethal dose (LD80) of acetaminophen (600 mg/kg, ip) survived if CBZ was administered 1 h after acetaminophen, suggesting that calpain-mediated progression of liver injury is neither species nor chemical specific. These findings suggest the role of calpain in progression of liver injury.
D000082:Acetaminophen / Q000378:metabolism / Q000493:pharmacokinetics / Q000633:toxicity; D000818:Animals; D015153:Blotting, Western; D002154:Calpain / Q000037:antagonists & inhibitors / Q000097:blood / Q000378:metabolism*; D002251:Carbon Tetrachloride / Q000378:metabolism / Q000493:pharmacokinetics / Q000633:toxicity; D002352:Carrier Proteins / Q000378:metabolism; D056486:Chemical and Drug Induced Liver Injury; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D019392:Cytochrome P-450 CYP2E1 / Q000378:metabolism; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004151:Dipeptides / Q000494:pharmacology; D018450:Disease Progression; D022781:Hepatocytes / Q000201:enzymology*; D007150:Immunohistochemistry; D008107:Liver Diseases / Q000097:blood / Q000201:enzymology* / Q000473:pathology; D008297:Male; D051379:Mice; D008840:Microfilament Proteins / Q000378:metabolism; D009336:Necrosis; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D013049:Spectrin
D000082:Acetaminophen; D002154:Calpain; D002251:Carbon Tetrachloride; D002352:Carrier Proteins; D015853:Cysteine Proteinase Inhibitors; D019392:Cytochrome P-450 CYP2E1; D065691:Cytochrome P-450 CYP2E1 Inhibitors; D004151:Dipeptides; D008840:Microfilament Proteins; D013049:Spectrin; C058076:calpain inhibitor III